The European Patent Office (EPO) has published patent application EP4661903A1, filed by Pfizer Inc., related to nucleic acids and their therapeutic uses. The application, published on March 18, 2026, outlines specific nucleic acid sequences and their applications, including classifications such as A61K (Preparations for medical, dental or toilet purposes) and A61P (Specific therapeutic activity of chemical compounds or medicinal preparations). The designated states cover a broad range of European countries.

This publication represents a new patent filing and does not impose immediate compliance obligations on regulated entities. However, it is relevant for pharmaceutical companies and drug manufacturers operating within the EU, particularly concerning intellectual property rights, research and development, and potential licensing opportunities or challenges related to nucleic acid-based therapeutics. Compliance officers in the pharmaceutical sector should note this filing for its implications on patent landscapes and competitive intelligence.